Preliminary results from trials using dual-targeted CAR-Ts (CD19/CD22 or CD19/BCMA) have shown promising outcomes, particularly in adult patients with ALL and diffuse large B-cell lymphoma [23,24]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.